vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and AQUABOUNTY TECHNOLOGIES INC (AQB). Click either name above to swap in a different company.
AQUABOUNTY TECHNOLOGIES INC is the larger business by last-quarter revenue ($180.2K vs $169.0K, roughly 1.1× Aligos Therapeutics, Inc.). On growth, Aligos Therapeutics, Inc. posted the faster year-over-year revenue change (-72.1% vs -77.1%). Over the past eight quarters, AQUABOUNTY TECHNOLOGIES INC's revenue compounded faster (-47.5% CAGR vs -50.7%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
AquaBounty Technologies is a biotechnology and aquaculture company based in Maynard, Massachusetts, United States. The company is notable for its research and development of genetically modified fish. It aims to create products that aim to increase the productivity of aquaculture. As of 2020, sale of the company's AquAdvantage salmon has been approved in Canada and the United States. The company sold all of its operating farms and ceased fish production in 2024.
ALGS vs AQB — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $180.2K |
| Net Profit | — | $-50.5M |
| Gross Margin | — | — |
| Operating Margin | — | -16405.6% |
| Net Margin | — | -28035.1% |
| Revenue YoY | -72.1% | -77.1% |
| Net Profit YoY | 75.8% | -676.1% |
| EPS (diluted) | — | $-13.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | — | ||
| Q3 25 | $741.0K | — | ||
| Q2 25 | $965.0K | — | ||
| Q1 25 | $311.0K | — | ||
| Q4 24 | $606.0K | — | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | $1.1M | $180.2K | ||
| Q1 24 | $694.0K | $477.3K |
| Q4 25 | — | — | ||
| Q3 25 | $-31.5M | — | ||
| Q2 25 | $-15.9M | — | ||
| Q1 25 | $43.1M | — | ||
| Q4 24 | $-82.2M | — | ||
| Q3 24 | $-19.3M | — | ||
| Q2 24 | $5.1M | $-50.5M | ||
| Q1 24 | $-34.9M | $-11.2M |
| Q4 25 | — | — | ||
| Q3 25 | -3827.4% | — | ||
| Q2 25 | -1924.0% | — | ||
| Q1 25 | -6187.5% | — | ||
| Q4 24 | -3393.2% | — | ||
| Q3 24 | -1610.5% | — | ||
| Q2 24 | -2489.5% | -16405.6% | ||
| Q1 24 | -3176.7% | -529.4% |
| Q4 25 | — | — | ||
| Q3 25 | -4256.0% | — | ||
| Q2 25 | -1643.8% | — | ||
| Q1 25 | 13854.7% | — | ||
| Q4 24 | -13556.1% | — | ||
| Q3 24 | -1540.7% | — | ||
| Q2 24 | 477.0% | -28035.1% | ||
| Q1 24 | -5023.5% | -2337.9% |
| Q4 25 | — | — | ||
| Q3 25 | $-3.04 | — | ||
| Q2 25 | $-1.53 | — | ||
| Q1 25 | $-2.11 | — | ||
| Q4 24 | $-13.10 | — | ||
| Q3 24 | $-3.07 | — | ||
| Q2 24 | $0.81 | $-13.08 | ||
| Q1 24 | $-5.58 | $-2.90 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | $728.3K |
| Total DebtLower is stronger | — | $10.5M |
| Stockholders' EquityBook value | $53.5M | $103.3M |
| Total Assets | $88.5M | $127.4M |
| Debt / EquityLower = less leverage | — | 0.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | — | ||
| Q3 25 | $99.1M | — | ||
| Q2 25 | $122.9M | — | ||
| Q1 25 | $137.9M | — | ||
| Q4 24 | $56.9M | — | ||
| Q3 24 | $74.9M | — | ||
| Q2 24 | $94.5M | $728.3K | ||
| Q1 24 | $112.7M | $2.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $10.5M | ||
| Q1 24 | — | $8.4M |
| Q4 25 | $53.5M | — | ||
| Q3 25 | $71.8M | — | ||
| Q2 25 | $101.9M | — | ||
| Q1 25 | $116.4M | — | ||
| Q4 24 | $-29.0M | — | ||
| Q3 24 | $50.1M | — | ||
| Q2 24 | $67.2M | $103.3M | ||
| Q1 24 | $59.8M | $153.8M |
| Q4 25 | $88.5M | — | ||
| Q3 25 | $109.8M | — | ||
| Q2 25 | $134.7M | — | ||
| Q1 25 | $150.7M | — | ||
| Q4 24 | $70.1M | — | ||
| Q3 24 | $88.4M | — | ||
| Q2 24 | $108.8M | $127.4M | ||
| Q1 24 | $127.9M | $176.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.10× | ||
| Q1 24 | — | 0.05× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-4.3M |
| Free Cash FlowOCF − Capex | — | $-5.2M |
| FCF MarginFCF / Revenue | — | -2885.9% |
| Capex IntensityCapex / Revenue | — | 485.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-45.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | — | ||
| Q3 25 | $-24.3M | — | ||
| Q2 25 | $-15.5M | — | ||
| Q1 25 | $-20.9M | — | ||
| Q4 24 | $-18.4M | — | ||
| Q3 24 | $-20.1M | — | ||
| Q2 24 | $-19.5M | $-4.3M | ||
| Q1 24 | $-22.7M | $-4.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-5.2M | ||
| Q1 24 | — | $-5.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2885.9% | ||
| Q1 24 | — | -1161.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 485.1% | ||
| Q1 24 | — | 235.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
